Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial-Reference-Cited by-同舟云学术

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

Published:2008-05 Issue:9625 Volume:371 Page:1685-1694
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Muers Martin F,Stephens Richard J,Fisher Patricia,Darlison Liz,Higgs Christopher MB,Lowry Erica,Nicholson Andrew G,O'Brien Mary,Peake Michael,Rudd Robin,Snee Michael,Steele Jeremy,Girling David J,Nankivell Matthew,Pugh Cheryl,Parmar Mahesh KB

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050;Hodgson;Br J Cancer,2005

2. The European mesothelioma epidemic;Peto;Br J Cancer,1999

3. Global use of asbestos and the incidence of mesothelioma;Tossavainen;Int J Occup Environ Health,2004

4. Statement on malignant mesothelioma in the United Kingdom;Thorax,2001

5. A review of chemotherapy trials for malignant mesothelioma;Ryan;Chest,1998

Cited by 230 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rehabilitation for Functioning and Quality of Life in Patients with Malignant Pleural Mesothelioma: A Scoping Review;Current Oncology;2024-07-30

2. Mesothelioma: Pleural, Version 1.2024;Journal of the National Comprehensive Cancer Network;2024-03

3. The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical/surgical care: a narrative review;Journal of Thoracic Disease;2024-01

4. Malignant pleural mesothelioma mimics thoracic empyema: A case report;World Journal of Clinical Cases;2023-12-16

5. Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-09